Maksim Luzgin/iStock via Getty Images
The type 2 diabetes (T2D) drug market is poised to explode, reaching $136.2 billion by 2029, according to a new report from GlobalData.
For comparison, the market was $45.9 billion in 2019.
the data and The analytics firm predicts that the market will grow at a compound annual growth rate of 11.5%.
Growth will be driven by the introduction of new blockbuster drugs in the coming years, as well as more patients diagnosed with T2D in major markets.
The new GlobalData report, Type 2 diabetes market size and trendsmentions Novo Nordisk’s (NVO) once-weekly insulin isodec, a basal insulin, and Eli Lilly’s (New York Stock Exchange: LLY) HR basal insulin, also dosed once a week. Insulin isodec is scheduled to launch in 2024, with FC basal insulin two years later.
Both companies have other candidates in the late stages of development. Novo (NVO) has Icosema, a combination of insulin isodec and semaglutide, in phase 3. In December, Lilly (LLY) said it would advance orforglipron, an oral nom-peptide GLP-1 agonist, to phase 3 in 2023.
Lilly’s (LLY) GLP-1 receptor agonist (GLP-1RA)/gastric inhibitory polypeptide (GIP) receptor agonist, Mounjaro (tirzepatide), approved in May 2022, has met with strong acceptance. It posted $97.3 million in US sales in the third quarter of 2022.
In the third quarter, the latest quarter for which data is available, Novo (NVO) posted ~DKK101.8 billion (~$14.8 billion) in revenue from its diabetes franchise. Lilly’s (LLY) top-selling diabetes drug, Trulicity (dulaglutide), raised ~$1.9 billion.
Akash Patel, an analyst at Global Data Pharma, said once-weekly basal insulins are likely to gain significant market acceptance as their efficacy is equal to or even better than existing basal insulins such as glargine. and lispro, and with better patient compliance as they are taken. infrequent.
Patel added that Victoza (liraglutide) from Novo (NVO), Lantus (insulin glargine) from Sanofi (SNY) and Merck (New York Stock Exchange:MRK) Januvia (sitagliptin) has lost market share due to more convenient dosing with newer therapies.
He added that physician preference for sodium-glucose-linked transporter 2 (SGLT-2) inhibitor therapies, including AstraZeneca’s (NASDAQ:AZN) Farxiga (dapagliflozin) and Lilly (LLY)/Boehringer Ingelheim’s Jardiance (empagliflozin), due to their ability to also address cardiorenal comorbidities, is causing the erosion of the use of older drugs.
A GlobalData report from November 2022 found that Novo Nordisk (NVO) is set to continue its lead over Lilly (LLY) in the T2D market.
